SYNERGISTIC CANCER TREATMENT

• Main Authors: FONTAINE Shaun, SANTI Daniel V
• Format: Patent
• Language: English; Spanish
• Published: 29.05.2023
• Subjects: CHEMISTRY; COMPOSITIONS BASED THEREON; HUMAN NECESSITIES; HYGIENE; MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVINGCARBON-TO-CARBON UNSATURATED BONDS; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MEDICAL OR VETERINARY SCIENCE; METALLURGY; NANOTECHNOLOGY; ORGANIC MACROMOLECULAR COMPOUNDS; PERFORMING OPERATIONS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; THEIR PREPARATION OR CHEMICAL WORKING-UP; TRANSPORTING

Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects. Conjugados de inhibidores de topoisomerasa I enlazados a una macromolécula a través de un enlace que se somete a eliminación beta in situ en combinación con uno o más de un defecto estimado en la respuesta de daño de ADN (DDR) en un sujeto portador de cáncer, un inhibidor de punto de control del ciclo celular y/o un inhibidor DDR proporciona efectos mejorados para sujetos portadores de cáncer.